Icon Bioscience said today that the FDA has approved its application for Dexycu, a long-acting therapy designed to treat inflammation in patients who have had cataract surgery.
More than four million cataract surgeries are performed each year in the U.S., according to the privately-held biopharma company, and most patients treat inflammation in their eyes using medicated eye drops over the course of several weeks.
Get the full story at our sister site, Drug Delivery Business News.
The post Icon Bioscience wins FDA nod for long-acting cataract surgery drug appeared first on MassDevice.